Intas’ Biopharma facility is a testament to our commitment to providing accessible and qualitative healthcare globally. It is fuelled by a mission to provide affordable “biosimilars for billions” across niche segments such as oncology, autoimmune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. With filgrastim, Intas became the first-ever Indian company to launch a biosimilar in the highly regulated EU market [approved and marketed under the name Accofil™]. In 2018, it also became the first integrated player to launch a pegfilgrastim biosimilar across Europe [approved and marketed under the name Pelgraz™]. Today, the unit caters to highly regulated markets of the EU, UK and US, which demand the highest standards of drug quality.

Intas Biopharma Unit has extensive capabilities to develop bacterial and mammalian derived recombinant proteins, such as

• Growth Factors
• Hormones
• Monoclonal Antibodies

Microbial Fermentation & Mammalian Cell Culture Manufacturing capabilities encompass small-scale to large-scale…

• Microbial Fermentation
• Mammalian Cell Culture
• Protein & Antibody Purification
• Pegylation
• Lyophilization
• Aseptic Formulation and Fill-Finish

Market leading manufacturing facilities offering 50 kL future capacity